Literature DB >> 1453292

In vitro lymphocyte functions in the presence of bovine surfactant and its phospholipid fractions.

P Bartmann1, L Gortner, F Pohlandt, H Jaeger.   

Abstract

Endotracheal administration of human or xenogenic surfactant preparations is an effective treatment of the respiratory distress syndrome of preterm infants. The application of large amounts of phospholipids to the lung may result in a significant alteration of the local immune response. We studied the influence of the bovine surfactant preparation SF-RI 1 (Alveofact) on lymphocyte functions in vitro. PHA-induced cell proliferation and immunoglobulin synthesis in the presence of whole surfactant as well as six different defined phospholipids were investigated. A marked concentration-dependent suppression of immunoglobulin production independent of the immunoglobulin isotype and cell proliferation was observed in the range of 5 ng/ml-3 mg/ml of a single phospholipid (or SF-RI 1 respectively). It could be demonstrated that suppression of lymphocyte functions was only due to the phospholipid content of the surfactant preparation. These data indicate that in vivo immune functions may be significantly altered by the administration of exogenous surfactant. This may be particularly important in the presence of primary or secondary pulmonary infections.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1453292     DOI: 10.1515/jpme.1992.20.3.189

Source DB:  PubMed          Journal:  J Perinat Med        ISSN: 0300-5577            Impact factor:   1.901


  3 in total

Review 1.  The Role of Surfactant in Lung Disease and Host Defense against Pulmonary Infections.

Authors:  SeungHye Han; Rama K Mallampalli
Journal:  Ann Am Thorac Soc       Date:  2015-05

2.  Coccidioides posadasii infection alters the expression of pulmonary surfactant proteins (SP)-A and SP-D.

Authors:  Shanjana Awasthi; D Mitchell Magee; Jacqueline J Coalson
Journal:  Respir Res       Date:  2004-12-10

3.  Impact of the New Generation Reconstituted Surfactant CHF5633 on Human CD4+ Lymphocytes.

Authors:  Markus Fehrholz; Kirsten Glaser; Silvia Seidenspinner; Barbara Ottensmeier; Tore Curstedt; Christian P Speer; Steffen Kunzmann
Journal:  PLoS One       Date:  2016-04-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.